BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares dropped 2.3% on Monday . The stock traded as low as $2.50 and last traded at $2.52, with a volume of 233,882 shares traded. The stock had previously closed at $2.58.

BDSI has been the topic of several recent research reports. Roth Capital reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Monday, March 28th. Laidlaw decreased their price target on shares of BioDelivery Sciences International from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, March 14th. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Tuesday, July 5th. FBR & Co reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a research report on Saturday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.38.

The company’s market capitalization is $134.52 million. The firm’s 50-day moving average is $2.36 and its 200-day moving average is $3.27.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.01. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The business had revenue of $3 million for the quarter, compared to the consensus estimate of $2.96 million. The company’s revenue was down 77.1% compared to the same quarter last year. Equities analysts predict that BioDelivery Sciences International Inc. will post ($1.19) EPS for the current fiscal year.

A number of hedge funds recently added to or reduced their stakes in BDSI. Sei Investments Co. increased its stake in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock valued at $1,584,000 after buying an additional 233,519 shares in the last quarter. 1492 Capital Management LLC increased its stake in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock valued at $2,580,000 after buying an additional 41,069 shares in the last quarter. Bank of Montreal Can increased its stake in BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock valued at $3,971,000 after buying an additional 28,838 shares in the last quarter. Turner Investments L.P. increased its stake in BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock valued at $4,315,000 after buying an additional 321,290 shares in the last quarter. Finally, Russell Frank Co increased its stake in BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock valued at $5,151,000 after buying an additional 394,272 shares in the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.